Spectrum Pharma (SPPI) Tops Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update
March 8, 2017 4:02 PM ESTROLONTIS (eflapegrastim) pivotal program is on track for Spectrum to file BLA next year. Poziotinib study in non-small cell lung cancer patients with EGFR Exon 20 insertion mutations, being run in partnership with The University of Texas MD Anderson Cancer Center, is expected to yield results before year end. Qapzola (apaziquone) receives a new Special Protocol Assessment (SPA) from the FDA that significantly reduces the number of patients required for NDA filing. Q4 revenues were $35.2 million, including $32.2 million in product sales.
HENDERSON,... More
